NDAORALSUSPENSIONPriority Review
Approved
Feb 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEPRON (atovaquone) is an oral antimalarial suspension approved in 1995 for treatment of Pneumocystis jirovecii pneumonia, malaria, toxoplasmosis, and HIV-related opportunistic infections. It functions as a small-molecule inhibitor with broad activity across parasitic and protozoal pathogens. The drug addresses life-threatening infections in immunocompromised populations, particularly those with advanced HIV disease.
$0.322MPart D
LOE ApproachingDeclining
Approaching loss of exclusivity with minimal active sales infrastructure; brand team likely in maintenance mode with reduced headcount expectations.
Mechanism of Action
Pharmacologic Class:
Antimalarial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC
Started Dec 2020
21 enrolled
Locally Advanced Non-Small Cell Lung Cancer
Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension
Started Apr 2012
30 enrolled
Malaria
Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America
Started Jul 2004
244 enrolled
Malaria, Falciparum
A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides
700 enrolled
Pneumonia, Pneumocystis CariniiHIV Infections
Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis
100 enrolled
Toxoplasmosis, CerebralHIV Infections
Worked on MEPRON at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.